Literature DB >> 12203125

Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.

Sally Hopkins-Donaldson1, Pu Yan, Katia Balmas Bourloud, Annick Muhlethaler, Jean-Luc Bodmer, Nicole Gross.   

Abstract

Death induced by doxorubicin (dox) in neuroblastoma (NB) cells was originally thought to occur via the Fas pathway, however since studies suggest that caspase-8 expression is silenced in most high stage NB tumors, it is more probable that dox-induced death occurs via a different mechanism. Caspase-8 silenced N-type invasive NB cell lines LAN-1 and IMR-32 were investigated for their sensitivity to dox, and compared to S-type noninvasive SH-EP NB cells expressing caspase-8. All cell lines had similar sensitivities to dox, independently of caspase-8 expression. Dox induced caspase-3, -7, -8 and -9 and Bid cleavage in S-type cells and death was blocked by caspase inhibitors but not by oxygen radical scavenger BHA. In contrast, dox-induced death in N-type cells was caspase-independent and was inhibited by BHA. Dox induced a drop in mitochondrial membrane permeability in all cell lines. Dox-induced death in S-type cells gave rise to apoptotic nuclei, whereas in N-type cells nuclei were non-apoptotic in morphology. Transfection of SH-EP cells with a dominant negative FADD mutant inhibited TRAIL-induced death, but had no effect on dox-induced apoptosis. These results suggest that S-type cells undergo apoptosis after dox treatment independently of death receptors, whereas N-type cells are killed by a caspase-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203125     DOI: 10.1038/sj.onc.1205879

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.

Authors:  Jana Hřebačková; Jitka Poljaková; Tomáš Eckschlager; Jan Hraběta; Pavel Procházka; Svatopluk Smutný; Marie Stiborová
Journal:  Interdiscip Toxicol       Date:  2009-09-28

2.  DNA and histone deacetylases as targets for neuroblastoma treatment.

Authors:  Marie Stiborová; Jitka Poljaková; Tomáš Eckschlager; Rene Kizek; Eva Frei
Journal:  Interdiscip Toxicol       Date:  2010-06

Review 3.  New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.

Authors:  Nina F Schor
Journal:  Pharmacol Ther       Date:  2009-01-23       Impact factor: 12.310

4.  Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma.

Authors:  Xiaoying Shang; Susan M Burlingame; M Fatih Okcu; Ningling Ge; Heidi V Russell; Rachel A Egler; Rodney D David; Sanjeev A Vasudevan; Jianhua Yang; Jed G Nuchtern
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

5.  Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.

Authors:  Ziyan Lu; Yufeng Tian; Helen R Salwen; Alexandre Chlenski; Lucy A Godley; J Usha Raj; Qiwei Yang
Journal:  Anticancer Drugs       Date:  2013-06       Impact factor: 2.248

6.  Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.

Authors:  Annick Mühlethaler-Mottet; Marjorie Flahaut; Katia Balmas Bourloud; Katya Auderset; Roland Meier; Jean-Marc Joseph; Nicole Gross
Journal:  BMC Cancer       Date:  2006-08-24       Impact factor: 4.430

7.  Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.

Authors:  Noelia Casares; Marie O Pequignot; Antoine Tesniere; François Ghiringhelli; Stéphan Roux; Nathalie Chaput; Elise Schmitt; Ahmed Hamai; Sandra Hervas-Stubbs; Michel Obeid; Frédéric Coutant; Didier Métivier; Evelyne Pichard; Pierre Aucouturier; Gérard Pierron; Carmen Garrido; Laurence Zitvogel; Guido Kroemer
Journal:  J Exp Med       Date:  2005-12-19       Impact factor: 14.307

8.  Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.

Authors:  Veronica Veschi; Marialaura Petroni; Beatrice Cardinali; Carlo Dominici; Isabella Screpanti; Luigi Frati; Armando Bartolazzi; Alberto Gulino; Giuseppe Giannini
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

9.  Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.

Authors:  Annick Mühlethaler-Mottet; Roland Meier; Marjorie Flahaut; Katia Balmas Bourloud; Katya Nardou; Jean-Marc Joseph; Nicole Gross
Journal:  Mol Cancer       Date:  2008-06-12       Impact factor: 27.401

10.  Doxorubicin-provoked increase of mitotic activity and concomitant drain of G0-pool in therapy-resistant BE(2)-C neuroblastoma.

Authors:  Isabell Hultman; Linnea Haeggblom; Ingvild Rognmo; Josefin Jansson Edqvist; Evelina Blomberg; Rouknuddin Ali; Lottie Phillips; Bengt Sandstedt; Per Kogner; Shahrzad Shirazi Fard; Lars Ährlund-Richter
Journal:  PLoS One       Date:  2018-01-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.